Amycretin vs Retatrutide
Amycretin vs Retatrutide: Novo's GLP-1 + amylin co-agonist vs Lilly's GLP-1 + GIP + glucagon triple agonist. The two most-watched next-generation obesity compounds, both pre-approval.
The verdict
Two of the most-watched next-generation obesity compounds, and neither is approved yet. Amycretin is Novo's single-molecule GLP-1 plus amylin co-agonist, notable for having both an injectable and an oral form and for some of the highest early weight-loss numbers in the class. Retatrutide is Lilly's triple agonist (GLP-1, GIP, glucagon), which has posted the largest trial weight-loss figures in the class. Retatrutide is already in Phase 3; Amycretin is now advancing to it. If the headline is raw effect size, Retatrutide leads on the numbers so far; Amycretin's real draw is the oral option in a field that is almost entirely injectable. For now both are investigational, so source quality is the actual risk, not the mechanism.
Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs. Activates GLP-1 + amylin in a single injection. They're testing both an oral pill and a weekly injection. Phase 1/2 only, not available yet.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Which one should you pick?
Pick Amycretin if trial participants in obesity studies or followers of novo's next-generation pipeline.
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Still torn between Amycretin and Retatrutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.